Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Perkins Discovery Fund (PDFDX)

34.24
Net Asset Value
+1.72%
1 Day
+5.91%
Year-to-Date
Overall Morningstar Rating
Small growth
Style or Category
No Load
Sales Expenses
3.27%
Expense Ratio
High
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will invest, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of domestic companies with market capitalizations of under $1 billion at the time of purchase. The equity securities the fund may purchase consist mostly of common stock, although the fund may purchase preferred and convertible stocks.

Performance

1 month+8.08% 3 years-2.99%
3 months-0.90% 5 years+7.40%
1 year+4.49% Since inception+9.40%
Data through --

Peer Comparisonvs. Small growth

 PDFDXCategory
Performance 5-yr return+7.40%+14.42%
Expense ratio3.27%1.33%
Risk 5 year sharpe ratio0.430.75
Net assets$7.0M$846.2M
Average market cap$453.3M$2.9B
Average P/E--24.6
Portfolio turnover2%2%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyPerkins
Fund manager & tenureRichard Perkins / 18 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00

Holdings

U.S. stock100.00%
International stock0.00%
Fixed income0.00%
Cash0.00%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 27.99%
Media 15.46%
Consumer service 10.21%
Energy 5.80%
Hardware 4.68%
Top 10 Holdings
Portfolio weighting
DEPO Depomed Inc10.29%
CSII Cardiovascular Systems Inc9.77%
SNAK Inventure Foods Inc8.38%
AXGN AxoGen Inc7.43%
PLUS ePlus inc6.48%
NEO Neogenomics Inc5.64%
ATRC AtriCure Inc5.43%
USPH U.S. Physical Therapy Inc5.38%
RMTI Rockwell Medical Inc4.60%
BEAT BioTelemetry Inc3.82%